cholera vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.

Top Publications

  1. ncbi Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638
    A Talavera
    Finlay Institute, 27 Ave, 19805 La Lisa, Ciudad de La Habana, A P 16017, Cod 11600, Cuba
    Vaccine 24:3746-9. 2006
  2. ncbi Cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Dhaka, Bangladesh
    Lancet 363:223-33. 2004
  3. doi Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Lancet 374:1694-702. 2009
  4. pmc Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania
    Mohammad Ali
    International Vaccine Institute, Kwanak PO Box 14, Seoul, 151 600, Republic of Korea
    Bull World Health Organ 88:556-9. 2010
  5. pmc The case for reactive mass oral cholera vaccinations
    Rita Reyburn
    International Vaccine Institute IVI, Seoul, Korea
    PLoS Negl Trop Dis 5:e952. 2011
  6. doi Oral vaccines against cholera
    Sunheang Shin
    International Vaccine Institute, Seoul, South Korea
    Clin Infect Dis 52:1343-9. 2011
  7. pmc Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice
    Stefan Schild
    Department of Molecular Biology and Microbiology, Howard Hughes Medical Institute, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Infect Immun 76:4554-63. 2008
  8. pmc Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    PLoS Negl Trop Dis 5:e1289. 2011
  9. pmc Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera
    Stefan Schild
    Howard Hughes Medical Institute and Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Infect Immun 77:472-84. 2009
  10. pmc Controlling endemic cholera with oral vaccines
    Ira M Longini
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e336. 2007

Research Grants

Detail Information

Publications166 found, 100 shown here

  1. ncbi Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638
    A Talavera
    Finlay Institute, 27 Ave, 19805 La Lisa, Ciudad de La Habana, A P 16017, Cod 11600, Cuba
    Vaccine 24:3746-9. 2006
    ..We conclude that the non-reactogenic, immunogenic and protective strain 638 is robust and can withstand the fermentation processes required for large-scale production of a vaccine...
  2. ncbi Cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Dhaka, Bangladesh
    Lancet 363:223-33. 2004
    ..Appropriate case management has reduced deaths from diarrhoeal disease by an estimated 3 million per year compared with 20 years ago. Vaccination was thought to have no role for cholera, but new oral vaccines are showing great promise...
  3. doi Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Lancet 374:1694-702. 2009
    Oral cholera vaccines consisting of killed whole cells have been available for many years, but they have not been used extensively in populations with endemic disease...
  4. pmc Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania
    Mohammad Ali
    International Vaccine Institute, Kwanak PO Box 14, Seoul, 151 600, Republic of Korea
    Bull World Health Organ 88:556-9. 2010
    ..Field trials require extensive data preparation and complex logistics. The use of personal digital assistants (PDAs) can bypass many of the traditional steps that are necessary in a paper-based data entry system...
  5. pmc The case for reactive mass oral cholera vaccinations
    Rita Reyburn
    International Vaccine Institute IVI, Seoul, Korea
    PLoS Negl Trop Dis 5:e952. 2011
    ..for the long term control of cholera, there is controversy about the role of newer approaches such as oral cholera vaccines (OCVs)...
  6. doi Oral vaccines against cholera
    Sunheang Shin
    International Vaccine Institute, Seoul, South Korea
    Clin Infect Dis 52:1343-9. 2011
    ..The advent of safe and effective, new-generation oral vaccines against cholera has created renewed interest in the use of vaccines as a tool to control cholera...
  7. pmc Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice
    Stefan Schild
    Department of Molecular Biology and Microbiology, Howard Hughes Medical Institute, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Infect Immun 76:4554-63. 2008
    ..These findings may contribute to the development of "nonliving," OMV-based vaccines against V. cholerae and other enteric pathogens, using the oral or intranasal route of immunization...
  8. pmc Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    PLoS Negl Trop Dis 5:e1289. 2011
    Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.
  9. pmc Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera
    Stefan Schild
    Howard Hughes Medical Institute and Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Infect Immun 77:472-84. 2009
    ..The detection of an immune response against this heterologously expressed protein is a promising step toward the potential use of OMVs as antigen delivery vehicles in vaccine design...
  10. pmc Controlling endemic cholera with oral vaccines
    Ira M Longini
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e336. 2007
    ..Internationally licensed, killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but have not been used for the control of cholera...
  11. pmc Vaccination strategies for epidemic cholera in Haiti with implications for the developing world
    Dennis L Chao
    Center for Statistics and Quantitative Infectious Diseases, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 108:7081-5. 2011
    ..Interventions have included treatment of cases and improved sanitation. Use of cholera vaccines would likely have further reduced morbidity and mortality, but such vaccines are in short supply and little ..
  12. pmc Mass vaccination with a two-dose oral cholera vaccine in a refugee camp
    D Legros
    Epicentre, Kampala, Uganda
    Bull World Health Organ 77:837-42. 1999
    In refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions...
  13. pmc Community participation in two vaccination trials in slums of Kolkata, India: a multi-level analysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    J Health Popul Nutr 28:450-7. 2010
    ..The results illustrated that participation in the trial was mostly influenced by various individual and community-level factors, which need to be addressed for a successful vaccination campaign...
  14. pmc Vibrio cholerae: lessons for mucosal vaccine design
    Anne L Bishop
    Department of Molecular Biology and Microbiology, Tufts University School of Medicine and Howard Hughes Medical Institute, Boston, MA 02111, USA
    Expert Rev Vaccines 10:79-94. 2011
    ..will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed...
  15. pmc Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility
    Anne L Bishop
    Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA 02111, USA
    Infect Immun 78:4402-20. 2010
    ..cholerae motility in vitro, with trends that parallel in vivo protection. Motility assays also reveal that a higher antibody titer is required to immobilize O139 compared to O1, a phenotype that is O139 capsule dependent...
  16. doi Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis
    Marc Jeuland
    Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Value Health 12:899-908. 2009
    ..Our analysis incorporated new findings on vaccine herd protective effects...
  17. ncbi Effectiveness of mass oral cholera vaccination in Beira, Mozambique
    Marcelino E S Lucas
    Ministry of Health, Maputo, Mozambique
    N Engl J Med 352:757-67. 2005
    New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa...
  18. pmc Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans
    M Jertborn
    Department of Medical Microbiology and Immunology, Department of Gastroenterology, Sahlgrenska University Hospital, Goteborg, Sweden
    Infect Immun 69:4125-8. 2001
    ..Antitoxin antibody responses in rectal secretions and serum were also found...
  19. doi Private demand for cholera vaccines in Hue, Vietnam
    Dohyeong Kim
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Value Health 11:119-28. 2008
    This study aims to measure the private demand for oral cholera vaccines in Hue, Vietnam, an area of relatively low endemicity of cholera, using the contingent valuation method.
  20. doi Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge
    Juthika Kundu
    Division of Microbiology, Central Drug Research Institute, Lucknow, India
    FEMS Immunol Med Microbiol 56:179-84. 2009
    ..Thus, mucosal codelivery of pertinent cholera toxoids provides enhanced protection against experimental cholera...
  21. ncbi When should cholera vaccine be used in cholera-endemic areas?
    David A Sack
    J Health Popul Nutr 21:299-303. 2003
  22. pmc Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy
    Ramadhan Hashim
    International Vaccine Institute, Seoul, Korea
    PLoS Negl Trop Dis 6:e1743. 2012
    Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine...
  23. doi Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Hum Vaccin 7:1299-308. 2011
    ....
  24. pmc Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera
    Mohammad Murshid Alam
    Immunology Unit, Laboratory Sciences Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Mohakali, Dhaka 1212, Bangladesh
    Clin Vaccine Immunol 18:844-50. 2011
    ..These findings may explain in part the relatively short-term protection afforded by oral cholera vaccination compared to natural disease...
  25. pmc Use of oral cholera vaccines in an outbreak in Vietnam: a case control study
    Dang Duc Anh
    National Institute of Hygiene and Epidemiology NIHE, Hanoi, Vietnam
    PLoS Negl Trop Dis 5:e1006. 2011
    Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam, which produces its own vaccine...
  26. doi Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age
    Amit Saha
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    Vaccine 29:8285-92. 2011
    ..Safety and immunogenicity study of an oral, killed, bivalent whole-cell, cholera vaccine, Shanchol was carried out in Bangladeshi participants. This study was conducted prior to initiating a feasibility study in Bangladesh...
  27. ncbi Private demand for cholera vaccines in Beira, Mozambique
    Marcelino E S Lucas
    Ministry of Science and Technology, Maputo, Mozambique
    Vaccine 25:2599-609. 2007
    ..We estimate average household willingness to pay (WTP) for cholera vaccines in Beira to be 2005 US$ 8.45...
  28. pmc Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR
    P J Cooper
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 69:1574-80. 2001
    ..The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas...
  29. doi Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera
    Tomas Jelinek
    Berlin Center for Travel and Tropical Medicine, Berlin, Germany
    Expert Rev Vaccines 7:561-7. 2008
    ..Vaccination against cholera and ETEC should be recommended for at-risk travelers, in particular those with high exposure at their travel destination or high personal risks through fluid loss...
  30. ncbi Efficacy calculation in randomized trials: global or local measures?
    Michael Emch
    Department of Geography, Saunders Hall, University of North Carolina, Chapel Hill, NC 27599 3220 USA
    Health Place 13:238-48. 2007
    ..Local efficacy measures can help public health practitioners make better decisions about when and where to vaccinate populations. The concepts offered in this study are pertinent for any health intervention trial, not just vaccines...
  31. doi New-generation vaccines against cholera
    John Clemens
    International Vaccine Institute, Seoul National University Research Park, San 4 8, Nakseongdae dong, Kwanak gu, Seoul 151 919, Korea
    Nat Rev Gastroenterol Hepatol 8:701-10. 2011
    ..Although early-generation parenteral cholera vaccines were abandoned as public health tools owing to their limited efficacy, newer-generation oral cholera vaccines ..
  32. ncbi Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development
    J J Mekalanos
    Nature 306:551-7. 1983
    ..Incorporation of defined in vitro-generated ctx deletion mutations into Vibrio cholerae by in vivo genetic recombination produced strains which have practical value in cholera vaccine development...
  33. ncbi Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase
    Duncan E S Stewart-Tull
    Division of Infection and Immunity, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
    Vaccine 22:2137-45. 2004
    ..cholerae cells and hence reduce delivery of toxin to receptors. These mucinases, neuraminidase and proteinases, may be useful components of acellular, toxoided cholera vaccines for human immunisation.
  34. pmc Social and cultural determinants of oral cholera vaccine uptake in Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Hum Vaccin Immunother 8:1223-9. 2012
    ..Findings recommend particular efforts to increase cholera immunization coverage among young adults, in peri-urban areas and for men...
  35. ncbi Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam
    A B Naficy
    Epidemiology Branch, National Institute of Child Health and Human Development, 6100 Executive Blvd, Suite 7B03, Rockville, MD 20852, USA
    Vaccine 19:3720-5. 2001
    ..91 per fully immunized person. Attempts to reduce the cost per dose of vaccine (e.g. the use of a monovalent vaccine against serogroup 01) are likely to have a large impact on the cost of future similar immunization campaigns...
  36. ncbi Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR
    P J Cooper
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0425, USA
    J Infect Dis 182:1199-206. 2000
    ..lumbricoides infections impair the immune response to oral cholera vaccine, particularly in subjects of non-O blood groups...
  37. pmc Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera
    J Murray
    BASICS Basic Support for Institutionalizing Child Survival, Arlington, VA 22209, USA
    Bull World Health Organ 76:343-52. 1998
    ..cholera with high incidence and associated mortality among refugees have raised the question of whether oral cholera vaccines should be considered as an additional preventive measure in high-risk populations...
  38. ncbi Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    Lancet 366:44-9. 2005
    Decisions about the use of killed oral cholera vaccines, which confer moderate levels of direct protection to vaccinees, can depend on whether the vaccines also provide indirect (herd) protection when high levels of vaccine coverage are ..
  39. doi Cholera in disasters: do vaccines prompt new hopes?
    Claire Lise Chaignat
    Global Task Force on Cholera Control, Department of Neglected Tropical Diseases, Communicable Diseases Cluster, World Health Organization, 20, Av Appia, 1211 Geneva 27, Switzerland
    Expert Rev Vaccines 7:431-5. 2008
    ..Fears of cholera outbreaks are often rife in such conditions and the pertinence of using cholera vaccines, now available on the market, merit attention...
  40. doi What about cholera vaccines?
    Claire Lise Chaignat
    Expert Rev Vaccines 7:403-5. 2008
  41. doi Cholera: the need to translate research knowledge into effective preventive and control measures
    G Balakrish Nair
    Future Microbiol 3:379-81. 2008
  42. pmc Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine
    Daisuke Tokuhara
    Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Proc Natl Acad Sci U S A 107:8794-9. 2010
    ..cholerae and LT-ETEC challenges. Thus, MucoRice-CTB is an effective long-term cold chain-free oral vaccine that induces CTB-specific SIgA-mediated longstanding protection against V. cholerae- or LT-ETEC-induced diarrhea...
  43. pmc Novel type of specialized transduction for CTX phi or its satellite phage RS1 mediated by filamentous phage VGJ phi in Vibrio cholerae
    Javier Campos
    Departamento de Genetica, Centro Nacional de Investigaciones Cientificas, AP 6412, Havana, Cuba
    J Bacteriol 185:7231-40. 2003
    ..cholerae and the importance of our findings for the development of an environmentally safer live attenuated cholera vaccine...
  44. ncbi Getting serious about cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    N Engl J Med 355:649-51. 2006
  45. ncbi Oral cholera vaccines: use in clinical practice
    David R Hill
    National Travel Health Network and Centre, London, UK
    Lancet Infect Dis 6:361-73. 2006
    Cholera continues to occur globally, particularly in sub-Saharan Africa and Asia. Oral cholera vaccines have been developed and have now been used for several years, primarily in traveller populations...
  46. ncbi Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults
    Dang Duc Anh
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 25:1149-55. 2007
    ..We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic...
  47. ncbi The true burden and risk of cholera: implications for prevention and control
    Jane N Zuckerman
    Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, Royal Free and University College Medical School, London, UK
    Lancet Infect Dis 7:521-30. 2007
    ..However, a vaccine against cholera is now available that has proven efficacy and tolerability in mass vaccination campaigns in low-income countries, and among travellers...
  48. doi Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial
    Suman Kanungo
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Vaccine 27:6887-93. 2009
    ..Responses to V. cholerae O139 were less pronounced but followed a similar pattern. We demonstrate that in a cholera-endemic area, the vaccine elicited vibriocidal responses after a single-dose of the vaccine...
  49. pmc A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India
    Dilip Mahalanabis
    Society for Applied Studies, Kolkata, India
    PLoS ONE 3:e2323. 2008
    ..This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India...
  50. ncbi Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS
    R Lopez-Gigosos
    International Vaccination Centre, Offices of the Health Area, Sub Delegation of the Government of Malaga, Paseo Marítimo de Pablo Ruiz Picasso 43, Malaga 29070, Spain
    Travel Med Infect Dis 5:380-4. 2007
    ..To investigate the effectiveness of an oral cholera vaccine (Dukoral((R))) in preventing travellers' diarrhoea...
  51. ncbi Private demand for cholera vaccines in rural Matlab, Bangladesh
    Ziaul Islam
    Health Systems and Infectious Diseases Division, International Centre for Diarrhoeal Disease Research ICDDR, B, Dhaka, Bangladesh
    Health Policy 85:184-95. 2008
    To estimate household willingness to pay (WTP) for cholera vaccines in a rural area of Bangladesh, which had participated in a 1985 oral cholera vaccine trial.
  52. ncbi Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines
    Jean François Faucher
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Clin Infect Dis 35:1147-54. 2002
    ..The A-P combination was highly effective for malaria prophylaxis, without interfering with the in vivo immunogenicity of CVD103-HgR and Ty21a vaccines, and it could therefore be simultaneously administered with these vaccines...
  53. ncbi Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity
    Michael Emch
    Department of Geography, Saunders Hall, Campus Box 3220, University of North Carolina Chapel Hill, 27599 3220, USA
    Int J Epidemiol 35:1044-50. 2006
    ....
  54. ncbi Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam
    Dinh Thiem Vu
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    J Health Popul Nutr 21:304-8. 2003
    ..89. Mass immunization with this locally-produced oral, killed cholera vaccine was found to be feasible and affordable with attainment of high vaccination coverage...
  55. ncbi Can oral cholera vaccination play a role in controlling a cholera outbreak?
    Philippe Calain
    WHO Western Pacific Regional Office, Manila, Philippines
    Vaccine 22:2444-51. 2004
    ..9-84.6%) in the target population. Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with ..
  56. ncbi Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children
    H O Hallander
    Swedish Institute for Infectious Disease Control, Solna, Sweden
    Vaccine 21:138-45. 2002
    Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in León, Nicaragua and one in Stockholm, Sweden...
  57. pmc The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers
    Luis Garcia
    Centro Nacional de Investigaciones Cientificas, P O Box 6412, Avenida 25, Esquina a 158, Ciudad de La Habana, Cuba
    Infect Immun 73:3018-24. 2005
    ..cholerae 3008. We recommend that additional vaccine lots of 638 be prepared under good manufacturing practices for further evaluation...
  58. ncbi The value of cholera vaccines reassessed
    Roger I Glass
    Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 366:7-9. 2005
  59. ncbi Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh ICDDR, B Centre for Health and Population Research, Dhaka, Bangladesh
    J Infect Dis 192:573-9. 2005
    ..A lower immunological response against cholera toxin B subunit was detected.CONCLUSIONS. The safety and immunogenicity of this Peru-15 vaccine candidate indicates the usefulness of future studies in Bangladesh, where cholera is endemic...
  60. ncbi Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam
    Vu Dinh Thiem
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 24:4297-303. 2006
    ..The overall vaccine effectiveness 3-5 years after vaccination was 50% (9-63%). This low-cost, easily administered vaccine should be considered as a tool for the control of cholera...
  61. ncbi Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants
    Firdausi Qadri
    ICDDR, B Centre for Health and Population Research, Bangladesh
    Vaccine 25:231-8. 2007
    ..The responses to the reduced dose was lower. These studies demonstrate that Peru-15 at a dose of 2x10(8)cfu is safe and immunogenic in children in Bangladesh...
  62. ncbi Vaccines on trial
    Paroma Basu
    Nature 436:484. 2005
  63. pmc Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO
    Claire Lise Chaignat
    Global Task Force on Cholera Control, World Health Organization, Avenue Appia 20, CH 1211 Geneva 27, Switzerland
    J Health Popul Nutr 25:244-61. 2007
    Two meetings of the World Health Organization (WHO)-in 1999 and 2002-had examined the potential use of oral cholera vaccines (OCVs) as an additional public-health tool for the control of cholera...
  64. ncbi Cholera vaccines for the developing world
    Anna Lena Lopez
    International Vaccine Institute, Seoul, Korea
    Hum Vaccin 4:165-9. 2008
    ..Since 1999, the World Health Organization has advocated the use of oral cholera vaccines as an adjunct in the control of cholera...
  65. ncbi [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea]
    Herwig Kollaritsch
    Institut für Spezifische Prophylaxe und Tropenmedizin, Zentrum für Physiologie und Pathophysiologie, Medizinische Universität Wien, Kinderspitalgasse 15, Vienna, Austria
    Wien Med Wochenschr 157:102-6. 2007
    ..Both vaccines display 85-98% efficacy against severe rotavirus disease and an excellent tolerability with no difference in side reactions to the placebo controls, particularly with respect to intussusceptions...
  66. ncbi Cholera: a new homeland in Africa?
    Nicholas H Gaffga
    Division of Foodborne, Mycotic, and Enteric Diseases, National Center for Zoonotic, Vectorborne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Trop Med Hyg 77:705-13. 2007
    ..The persistence or control of cholera in Africa will be a key indicator of global efforts to reach the Millennium Development Goals and of recent commitments by leaders of the G-8 countries to increase development aid to the region...
  67. pmc Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka
    Infect Immun 73:6577-83. 2005
    ..cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines...
  68. ncbi Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR
    Jean Francois Viret
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018 Berne, Switzerland
    Vaccine 22:2457-69. 2004
    ..In this contribution we address selected aspects of the risk assessment of live attenuated bacterial vaccines covered in the course of the registration of vaccine strain CVD 103-HgR as a recombinant live oral vaccine against cholera...
  69. ncbi Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
    Vaccine 22:416-21. 2004
    ..Thus, zinc enhanced vibriocidal antibody response, but suppressed CT-antibody response, suggesting that zinc supplementation has different modulating effects on vibriocidal antibody response and CT-antibody response...
  70. pmc Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination
    C O Tacket
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 67:6341-5. 1999
    ..Peak stool V. cholerae excretion among placebo recipients was 1.1 x 10(7) CFU/g and among vaccinees was 4.9 x 10(2) CFU/g (P < 0.001). This vaccine could therefore be a safe and effective tool to prevent cholera in travelers...
  71. ncbi Sample size determination for phase II studies of new vaccines
    Malla R Rao
    National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    Vaccine 20:3364-9. 2002
    ..We also consider a setting in which the desire is to show that the difference between immune response rates for vaccine and control is greater than a specified value...
  72. pmc CTXphi immunity: application in the development of cholera vaccines
    H H Kimsey
    Division of Geographic Medicine and Infectious Diseases, Tupper Research Institute, Tufts New England Medical Center 041, 750 Washington Street, Boston, MA 02111, USA
    Proc Natl Acad Sci U S A 95:7035-9. 1998
    ..cholerae vaccine strains effectively protected these vaccines from CTXphi infection. Introduction of rstR into V. cholerae vaccine strains should enhance their biosafety...
  73. pmc Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice
    J Y Wu
    Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Infect Immun 69:7695-702. 2001
    ..These results indicate that specific regions of TcpA, including those delineated by the peptides used in this study, have the potential to be incorporated into an effective defined subunit vaccine for cholera...
  74. pmc A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali
    R T Perry
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
    Bull World Health Organ 76:63-71. 1998
    ..These results encourage further evaluations of this single-dose, oral cholera vaccine in high-risk populations such as refugees in sub-Saharan Africa...
  75. ncbi Cholera vaccines
    E T Ryan
    Tropical and Geographic Medicine Center, Travelers Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 31:561-5. 2000
    ..cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed.
  76. pmc Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139
    Stephen R Attridge
    Department of Molecular Biosciences, University of Adelaide, Adelaide, South Australia 5005, Australia
    Clin Diagn Lab Immunol 9:383-7. 2002
    ..Although infection generated stronger responses than vaccination, the proportion of responders was similar among individuals with low background titers...
  77. pmc Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam
    D D Trach
    National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam
    Bull World Health Organ 80:2-8. 2002
    ..To evaluate a killed oral cholera vaccine produced in Viet Nam, and to compare the Vietnamese vaccine with one that is licensed internationally...
  78. doi Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea
    Jonas Lundkvist
    i3innovus, Stockholm, Sweden
    J Travel Med 16:28-34. 2009
    ....
  79. ncbi Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea
    Robert Steffen
    Institute for Social and Preventive Medicine ISPM, World Health Organization WHO Collaborating Center for Travelers Health, University of Zurich, Switzerland
    J Travel Med 12:102-7. 2005
  80. ncbi A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection
    Meiying Yan
    State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, PR China
    Vaccine 25:4046-55. 2007
    ..Thus, IEM109 is a stable vaccine candidate that evokes not only antitoxic and vibriocidal immunities, but also resistance to the El Tor biotype CTX Phi infection...
  81. ncbi Cholera vaccines
    Shahjahan Kabir
    Lancet Infect Dis 7:176-8; author reply 178. 2007
  82. ncbi Construction and characterisation of O139 cholera vaccine candidates
    Talena Ledón
    Grupo de Genética, Centro Nacional de Investigaciones Cientificas, AP 6412 Havana, Cuba
    Vaccine 21:1282-91. 2003
    ..All the strains here obtained showed similar phenotypes in traits known to be remarkable for live cholera vaccines irrespective of their motility phenotypes, although the hapA mutants had a 10-fold decrease in their ..
  83. ncbi Progress towards development of a cholera subunit vaccine
    Ronald K Taylor
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biodivers 1:1036-57. 2004
    ..cholerae exposed or vaccinated individuals. This review discusses the current cholera vaccines and compares the advantages of a cholera subunit vaccine to that of the whole cell vaccines...
  84. ncbi The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine
    Daniele Provenzano
    Department of Biological Sciences, University of Texas Brownsville, Brownsville, TX 78520, USA
    Microbiol Immunol 50:899-927. 2006
    ....
  85. ncbi Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation
    Manickam Ravichandran
    Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Kelantan, Malaysia
    Vaccine 24:3750-61. 2006
    ..VCUSM2 is thus a potential vaccine candidate against infection by V. cholerae O139...
  86. ncbi Experience with registered mucosal vaccines
    Guido Dietrich
    Berna Biotech Ltd, Rehhagstr 79, CH 3018, Berne, Switzerland
    Vaccine 21:678-83. 2003
    ..typhi Ty21a as well as V. cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity...
  87. ncbi [Cholera: recent acquisitions]
    Salvatore Nardiello
    Dipartimento Assistenziale di Malattie Infettive, Seconda Universita degli Studi di Napoli
    Infez Med 15:85-92. 2007
    ..We have reviewed the most recent hypothesis on the ecology of cholera, in particular on the origin of epidemics. Recent developments in the fields of therapy and prophylaxis of cholera are also reported...
  88. ncbi Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles
    Ming Kung Yeh
    Department of Clinical Pharmacy and Clinical Pharmacy Research Laboratory, Room 6345, Tri Service General Hospital, National Defence Medical Center, 325 Sec 2 Chen kung R D, Neihu, 114, Taipei, Taiwan
    J Control Release 82:237-47. 2002
    ..The VC incorporation, physicochemical characterization data, and the animal results obtained in this study may be relevant in optimizing the vaccine incorporation and delivery properties of these potential vaccine targeting carriers...
  89. ncbi Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4
    Vu Dinh Thiem
    Vaccine 25:7981-3. 2007
  90. pmc DNA adenine methylase is essential for viability and plays a role in the pathogenesis of Yersinia pseudotuberculosis and Vibrio cholerae
    S M Julio
    Department of Molecular, University of California, Santa Barbara, California 93106, USA
    Infect Immun 69:7610-5. 2001
    ..Dysregulation of Dam activity may provide a means for the development of vaccines against varied bacterial pathogens...
  91. ncbi Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier
    Anatoly Chernyak
    Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 185:950-62. 2002
    ..Further studies are required to increase understanding of the reason for differential protection...
  92. ncbi [Selection of attenuated Vibrio cholerae strains to obtain oral attenuated candidate vaccines against cholera]
    Hilda María García
    Instituto Finlay, Ciudad de La Habana, Cuba
    Rev Cubana Med Trop 57:92-104. 2005
    ..All the strains were sensitive to tetracycline and doxoclycine. They showed their attenuation and immunogenicity in animal models. The strains 638 and 1333 proved to be immunogenic and non reactogenic in volunteers...
  93. ncbi Vibrio cholerae and cholera: out of the water and into the host
    Joachim Reidl
    Zentrum für Infektionsforschung, Universitat Wurzburg, Wurzburg, Germany
    FEMS Microbiol Rev 26:125-39. 2002
    ..More recently, researchers have been elucidating the environmental lifestyle of V. cholerae. This review provides an overview of the current knowledge of both the host- and environment-specific physiological attributes of V. cholerae...
  94. ncbi Home-grown Vietnamese cholera vaccine "completely safe"
    Mary Quirk
    Lancet Infect Dis 2:198. 2002
  95. ncbi A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses
    Jae Seung Yang
    Laboratory Sciences Division, International Vaccine Institute, Seoul 151 600, Republic of Korea
    J Microbiol Methods 71:141-6. 2007
    ....
  96. ncbi Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003
    Shahjahan Kabir
    Vaccine 25:1353-4. 2007
  97. pmc Detection of antibodies to toxin-coregulated pili in sera from cholera patients
    Stephen R Attridge
    Department of Molecular Biosciences, The University of Adelaide, Adelaide, South Australia, Australia
    Infect Immun 72:1824-7. 2004
    ..These MAbs were used in immunoblotting studies to assess seroconversion to El Tor TCP following cholera. Clear anti-pilus responses were observed in five of nine patients...
  98. pmc Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxins
    G Kenneth Haines
    Northwestern University, Dept of Microbiology Immunology, 303 E Chicago Avenue, Tarry 3 713, Chicago, IL 60611, USA
    Infect Immun 73:6157-64. 2005
    ..Morbidity is enhanced in C3H/HeJ mice, indicating that Toll-like receptor 4 is important for infection containment...
  99. pmc Exploiting cholera vaccines as a versatile antigen delivery platform
    Anisia J Silva
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr, SW Atlanta, GA 30310, USA
    Biotechnol Lett 30:571-9. 2008
    ..Foreign antigens can be delivered to the immune system with cholera vaccines by expressing heterologous antigens in live attenuated vectors, as fusion proteins with cholera toxin ..
  100. ncbi Prevention of cholera
    Noel W Preston
    Lancet 363:898. 2004

Research Grants75

  1. GENETIC ANALYSIS OF CHOLERA TOXIN STRUCTURE AND FUNCTION
    Randall K Holmes; Fiscal Year: 2010
    ..No vaccine against cholera or ETEC diarrhea is approved in the United States, and cholera vaccines used elsewhere have significant limitations...
  2. GENETIC ANALYSIS OF CHOLERA TOXIN STRUCTURE AND FUNCTION
    Randall Holmes; Fiscal Year: 2007
    ..No vaccine against cholera or ETEC diarrhea is approved in the United States, and cholera vaccines used elsewhere have significant limitations...
  3. Epidemiology and Ecology of Vibrio cholerae in Bangladesh
    Richard Bradley Sack; Fiscal Year: 2010
    ..The very recent availability of inexpensive oral cholera vaccines makes this objective even more relevant...
  4. Study of transmissible forms of Vibrio cholerae
    Andrew Camilli; Fiscal Year: 2007
    ..of transmission of this and perhaps other water-borne pathogens, it will aid in the development of new cholera vaccines that target the antigens of 'incoming' vibrios, and it may suggest new approaches for the prevention of the ..
  5. STUDY OF VIBRIO INTESTINAL PHYSIOLOGY AND PATHOGENICITY
    Andrew Camilli; Fiscal Year: 2004
    ..of virulence gene expression during infection of an intact host, but will aid in the development of new cholera vaccines and suggest new approaches for the prevention of the dissemination of this lethal organism.
  6. SIGMA54 AND VIBRIO CHOLERAE PATHOGENESIS
    KARL KLOSE; Fiscal Year: 2003
    ..54 and FlrC-dependent colonization genes and promoters may be useful in the development of live attenuated cholera vaccines, and manipulation of virulence factor repression could have practical applications for anti-cholera therapy.
  7. GENTICS DETERMINATION OF VIRULENCE OF VIBRIO CHOLERAE
    Ronald Taylor; Fiscal Year: 1993
    ..intelligently incorporate the participating molecules and any antigenic variants into the design of improved cholera vaccines. Most of this proposal involves a genetic analysis of TCP (toxin regulated pilus) mediated colonization...
  8. DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINE
    JAMES KAPER; Fiscal Year: 2007
    ..We have also generated new insights into intestinal inflammation caused by these reactogenic cholera vaccines by using gene arrays of epithelial cell transcriptional responses...
  9. DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINE
    James B Kaper; Fiscal Year: 2010
    ..We have also generated new insights into intestinal inflammation caused by these reactogenic cholera vaccines by using gene arrays of epithelial cell transcriptional responses...
  10. Causal inference in infectious disease prevention studies
    Michael G Hudgens; Fiscal Year: 2010
    ..A motivating data set is from a trial of cholera vaccines in Bangladesh...
  11. Causal inference in infectious disease prevention studies
    Michael G Hudgens; Fiscal Year: 2011
    ..A motivating data set is from a trial of cholera vaccines in Bangladesh...
  12. DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINE
    JAMES KAPER; Fiscal Year: 2005
    ..The development of attenuated cholera vaccines has been plagued by the fact that V...
  13. GENETIC ANALYSIS OF TOXINOGENESIS IN VIBRIO CHOLERAE
    John Mekalanos; Fiscal Year: 2007
    ..Finally, derivatives of 0395-N1 which are suitable for use as a dead, oral cholera vaccines will be constructed which hyperproduce the B subunit of the toxin in both a secreted and nonsecreted form.
  14. Cholera Pathogenesis, mucinase activity and motility
    Jorge Benitez; Fiscal Year: 2007
    ..cholerae main virulence factors: cholera toxin and toxin co-regulated in the infant mouse intestine. This knowledge will facilitate the development of improved cholera vaccines.
  15. Mucosal immune response to oral cholera vaccine Peru 15
    Firdausi Qadri; Fiscal Year: 2007
    ..cholerae. ..
  16. Global TravEpiNet: Global Travelers' Health National Research Center Consortium
    Edward Ryan; Fiscal Year: 2007
    ..We would use data generated through this network in an attempt to estimate national vaccine coverage rates (and other preventative strategies) among international travelers. ..
  17. Application of IVIAT to Bacillus anthracis
    Edward Ryan; Fiscal Year: 2004
    ..IVIAT is an established protocol in our laboratory, and this preliminary collaborative study should lay a foundation for subsequent analysis of identified B. anthracis genes and their products. ..
  18. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2006
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  19. High throughput proteomic analysis of Salmonella enterica
    Edward Ryan; Fiscal Year: 2007
    ....
  20. Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15
    Edward Ryan; Fiscal Year: 2007
    ..Protective immunity to V. cholerae is poorly understood, and development of highly effective cholera vaccines has been problematic...